Increased transforming growth factor-beta1 circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin

Journal of the American College of Cardiology

Volumn 39, Issue 11, 2002, Pages 1752-1757

  Porreca, Ettore ^a   Di Febbo, Concetta ^a   Baccante, Giovanna ^a   Di Nisio, Marcello ^a   Cuccurullo, Franco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PRAVASTATIN; STATIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CELL ISOLATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET THERAPY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CROSS-OVER STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MONOCYTES; PRAVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TRIGLYCERIDES;

EID: 0037024272     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01857-0     Document Type: Article

References (44)

1. Transforming growth factor-beta: Recent progress and new challenge
2. Role of transforming growth factor-beta in human disease
3. The pathogenesis of atherosclerosis: A perspective for 1990s
4. The emerging concept of vascular remodeling
5. Atherosclerosis: An inflammatory disease
6. 1
7. Big-h3, a transforming growth factor-beta-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions
8. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions: Colocalization implicates TGF-beta in fibrofatty lesion development
9. Cytokine expression in advanced human atherosclerotic plaques: Dominance of proinflammatory (Th1) and macrophage-stimulating citokines
10. 1 during repair of arterial injury
11. 1 is increased in human vascular restenosis lesions
12. Atherosclerosis: Coagulation and fibrinolysis
13. Active and acid-activatable TGF-beta in human sera, platelets and plasma
14. 1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer
15. 1) in blood: Assay development and comparison
16. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis
17. 1 and coronary, artery disease
18. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries
19. The evolving role of statins in the management of atherosclerosis
20. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation
21. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
22. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia
23. Inhibition of proinflammatory cytokine production by pravastatin
24. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia
25. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
26. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of ultracentrifuge
27. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin
28. Transforming growth factor-beta is sequestered into an inactive pool by lipoproteins
29. Increased transforming growth factor-beta production and gene expression by peripheral blood monocytes of hypertensive patients
30. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction
31. KK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronection production in balloon-injured rabbit carotid artery
32. 1 mRNA expression in diabetic rat glomeruli
33. 1 expression in diabetic rat glomeruli and cultured rat mesangial cells
34. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors upregulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase
35. Statins do more than just lower cholesterol
36. Regulation of the mevalonate pathway
37. Beta-type transforming growth factor species' organizational behavior in vascular smooth muscle cultures
38. 1 gene into arteries stimulates fibrocellular hyperplasia
39. 1 during repair of arterial injury
40. 1 suppress intimal hyperplasia in a rat model
41. 1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions
42. 1 and interleukin-1β stimulate LDL receptor activity in HepG2 cells
43. Transforming growth factor-beta upregulates low-density lipoprotein receptor-mediated cholesterol metabolism in vascular smooth muscle cells